Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer

Phase Ⅱ Non-randomized Multicenter Controlled Trial About Effect of Remnant Ablation Therapy on the Recurrence in Low-risk Differentiated Thyroid Cancer Patients

Status

UNKNOWN

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02418247

Enrollment

556

Registered

2015-04-16

Start date

2013-05-31

Completion date

2020-12-31

Last updated

2017-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid Neoplasms

Keywords

radioactive iodine therapy, ablation, thyroid cancer

Brief summary

The researchers investigated the rate of biochemical remission in patients without radioactive iodine therapy compared to patients with low dose radioactive iodine treatment in differentiated thyroid cancer patients who underwent total thyroidectomy.

Interventions

DRUGI131

DRUGI123

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 79 Years

Healthy volunteers

Inclusion criteria

* patients with differentiated thyroid cancer * recently underwent total thyroidectomy (within 6 months) * pathological criteria 1. T1bN0 : Tumor size 1-2cm with no microscopic extension with multifocality (within three foci) 2. T3N0 : Tumor size \<=2cm with microscopic extension (less than strap muscle) 3. T1-3N1a : 3 or less micrometastatic lymph node

Exclusion criteria

* differentiated thyroid cancer with aggressive variant, poorly differentiated thyroid cancer, medullary thyroid cancer, anaplastic thyroid cancer * gross extension (strap muscle or more) * thyroid cancer with distant metastasis * previous remote history of thyroid cancer surgery * history of cervical external beam radiation therapy * previous history of comorbid cancer within 5 years * renal insufficiency (Ccr \<30ml/min) * women with pregnancy or breast feeding

Design outcomes

Primary

Measure	Time frame
Biochemical Remission Rate	within 1 year since first thyroid hormone withdrawal regardless of radioactive iodine administration

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026